A victory for global public health in the Indian Supreme Court

被引：7

作者：

't Hoen, Ellen ^{[1
]}

机构：

[1] Univ Amsterdam, NL-1012 DK Amsterdam, Netherlands

来源：

JOURNAL OF PUBLIC HEALTH POLICY | 2013年 / 34卷 / 03期

关键词：

patents; generic drugs; innovation; drug prices;

D O I：

10.1057/jphp.2013.21

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

On 1 April of this year, the Indian Supreme Court upheld the decision of the Indian Patent Office to refuse the patent grant for Novartis imatinib mesylate (Gleevec). The patent application failed to meet the requirements for patentability under Indian law. The global public health community followed the case closely. Its outcome could affect the Indian generics industry - an important supplier of low cost medicines to the developing world.

引用

页码：370 / 374

页数：5